Figure 6

The sigma-2 ligand, SV119, combined with paclitaxel suppresses tumor growth and increases survival in model pancreatic adenocarcinoma in vivo. C57BL/6 mice bearing established tumor allografts were treated with daily SV119 (1 mg/mouse, i.p. for 7 days) and daily paclitaxel (0.3 mg/mouse, i.p. for 7 days). Mean tumor diameter (Panel A) and survival (Panel B) were measured. * = vs. control.